FDA
-
-
-
-
-
-
-
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
-
-
-
-
-
-
-
Belite Bio (BLTE) Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
-
-
-
-
-
-
-
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
-
-
-
-
-
-
-
Belite Bio (BLTE) Reports FY22, Provides Operational Highlights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

